Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2008 Feb;1(1):11-19.
doi: 10.1093/ndtplus/sfm022. Epub 2007 Dec 19.

Fabry nephropathy: 5 years of enzyme replacement therapy-a short review

Frédéric Barbey  1 , Olivier Lidove  2 , Andreas Schwarting  3
Affiliations
Editorial

Fabry nephropathy: 5 years of enzyme replacement therapy-a short review

Frédéric Barbey et al. NDT Plus. 2008 Feb.
No abstract available

Keywords: ACE inhibitors; Fabry disease; angiotensin receptor blockers; enzyme replacement therapy; kidney; nephropathy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The interrelationships between functional and morphological markers in diabetic and Fabry nephropathy. Great similarities are found between these conditions.
Fig. 2
Fig. 2
(A) Change in estimated glomerular filtration rate (eGFR) in 20 patients before and 1 year after the initiation of enzyme replacement therapy (ERT) with agalsidase alfa. eGFR 1 year before treatment, at baseline and 1 year after the start of ERT in 12 patients with a mean baseline GFR of 60–89 ml/min/1.73 m2 (top) and 8 patients with a mean eGFR of 30–59 ml/min/1.73 m2 (bottom). (B) Change in eGFR in 13 patients before and during 2 years after the initiation of ERT with agalsidase alfa. eGFR 1 year before treatment, at baseline and 1 and 2 years after the start of ERT in 8 patients with a mean baseline GFR of 60–89 ml/min/1.73 m2 (top) and 5 patients with a mean eGFR of 30–59 ml/min/1.73 m2 (bottom). Data are shown as mean (dot), median (rule) and 10th, 25th, 75th and 90th percentiles (box and whiskers). Adapted with permission from Schwarting et al. [41], courtesy of Dustri–Verlag.
See this image and copyright information in PMC

References

    1. Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163–1167. - PubMed
    1. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31–40. - PMC - PubMed
    1. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254. - PubMed
    1. Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in portugal. Eur J Hum Genet. 2004;12:87–92. - PubMed
    1. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–760. - PMC - PubMed

Publication types

LinkOut - more resources